fda approved glp-1 receptor agonists just orforglipron (Foundayo), Eli Lilly's oral agonist for obesity. In the ATTAIN-1 phase 3 trial (n=3,127), published in the New England Journal of Medicine, patients on the highest What the New FDA‑Approved Weight‑Loss
Pay in 4 interest-free payments of $6.15 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27


























